Q-omics provides the consensus-scored SLC35E4 profile across patient tissues and cancer cell-line models. SLC35E4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC35E4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SLC35E4 protein abundance shows 19,607 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where SLC35E4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35E4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35E4 survival associations across molecular data types. SLC35E4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35E4 RNA expression–survival associations across cancer types. High SLC35E4 expression shows unfavorable associations in ACC, LIHC, KICH, KIRC, LAML and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC35E4 RNA expression.
This table summarizes SLC35E4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC35E4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35E4 shows higher tumor expression in COAD, HNSC, LUAD, LIHC, KIRC and STAD. The COAD box plot shows higher SLC35E4 RNA expression in tumor versus normal tissue (log2 FC = +1.542, t-test p < 0.001).
This table shows molecular features associated with SLC35E4 in patient tissues and cancer cell lines. In patient samples, SLC35E4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35E4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
